486 related articles for article (PubMed ID: 15703510)
1. Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial.
Dagenais GR; Yi Q; Lonn E; Sleight P; Ostergren J; Yusuf S;
Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):75-81. PubMed ID: 15703510
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.
Sumner G; Salehian O; Yi Q; Healey J; Mathew J; Al-Merri K; Al-Nemer K; Mann JF; Dagenais G; Lonn E;
J Cardiovasc Electrophysiol; 2009 Jul; 20(7):781-7. PubMed ID: 19298567
[TBL] [Abstract][Full Text] [Related]
3. The HOPE Study (Heart Outcomes Prevention Evaluation).
Sleight P
J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
[TBL] [Abstract][Full Text] [Related]
4. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.
Can J Cardiol; 1996 Feb; 12(2):127-37. PubMed ID: 8605634
[TBL] [Abstract][Full Text] [Related]
5. Diabetes and the HOPE study: implications for macrovascular and microvascular disease.
Gerstein HC
Int J Clin Pract Suppl; 2001 Jan; (117):8-12. PubMed ID: 11715357
[TBL] [Abstract][Full Text] [Related]
6. Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.
Teo KK; Mitchell LB; Pogue J; Bosch J; Dagenais G; Yusuf S;
Circulation; 2004 Sep; 110(11):1413-7. PubMed ID: 15353497
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.
Bosch J; Lonn E; Pogue J; Arnold JM; Dagenais GR; Yusuf S;
Circulation; 2005 Aug; 112(9):1339-46. PubMed ID: 16129815
[TBL] [Abstract][Full Text] [Related]
8. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients.
Costanzo P; Perrone-Filardi P; Petretta M; Marciano C; Vassallo E; Gargiulo P; Paolillo S; Petretta A; Chiariello M
J Hypertens; 2009 Jun; 27(6):1136-51. PubMed ID: 19451836
[TBL] [Abstract][Full Text] [Related]
9. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study.
Stampfer MJ; Colditz GA; Willett WC; Manson JE; Rosner B; Speizer FE; Hennekens CH
N Engl J Med; 1991 Sep; 325(11):756-62. PubMed ID: 1870648
[TBL] [Abstract][Full Text] [Related]
10. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis.
Reboldi G; Angeli F; Cavallini C; Gentile G; Mancia G; Verdecchia P
J Hypertens; 2008 Jul; 26(7):1282-9. PubMed ID: 18550998
[TBL] [Abstract][Full Text] [Related]
11. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
Saha SA; Molnar J; Arora RR
J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
[TBL] [Abstract][Full Text] [Related]
12. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
[TBL] [Abstract][Full Text] [Related]
13. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.
McQueen MJ; Lonn E; Gerstein HC; Bosch J; Yusuf S
Scand J Clin Lab Invest Suppl; 2005; 240():143-56. PubMed ID: 16112972
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials.
Danchin N; Cucherat M; Thuillez C; Durand E; Kadri Z; Steg PG
Arch Intern Med; 2006 Apr; 166(7):787-96. PubMed ID: 16606817
[TBL] [Abstract][Full Text] [Related]
15. Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome.
Leung S; Gallup D; Mahaffey KW; Cohen M; Antman EM; Goodman SG; Harrington RA; Langer A; Aylward P; Ferguson JJ; Califf RM;
Am Heart J; 2008 Jul; 156(1):177-84. PubMed ID: 18585514
[TBL] [Abstract][Full Text] [Related]
16. Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
White HD; Aylward PE; Huang Z; Dalby AJ; Weaver WD; Barvik S; Marin-Neto JA; Murin J; Nordlander RO; van Gilst WH; Zannad F; McMurray JJ; Califf RM; Pfeffer MA;
Circulation; 2005 Nov; 112(22):3391-9. PubMed ID: 16301343
[TBL] [Abstract][Full Text] [Related]
17. Vitamin E increases the risk of developing heart failure after myocardial infarction: Results from the GISSI-Prevenzione trial.
Marchioli R; Levantesi G; Macchia A; Marfisi RM; Nicolosi GL; Tavazzi L; Tognoni G; Valagussa F;
J Cardiovasc Med (Hagerstown); 2006 May; 7(5):347-50. PubMed ID: 16645413
[TBL] [Abstract][Full Text] [Related]
18. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
Saha SA; Molnar J; Arora RR
Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
[TBL] [Abstract][Full Text] [Related]
19. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.
Gerstein HC
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S82-5. PubMed ID: 12324991
[TBL] [Abstract][Full Text] [Related]
20. High-risk myocardial infarction in the young: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial.
Anderson RE; Pfeffer MA; Thune JJ; McMurray JJ; Califf RM; Velazquez E; White HD; Rouleau JL; Skali H; Maggioni A; Solomon SD
Am Heart J; 2008 Apr; 155(4):706-11. PubMed ID: 18371480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
